Antibody-drug conjugates in solid tumors; new strategy for cancer therapy

Abstract Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds to the specific antigen present at the cancer cells, allowing selective delivery of the cytotox...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 2024-05, Vol.54 (8), p.837-846
Main Authors: Takakura, Toshiaki, Shimizu, Toshio, Yamamoto, Nobuyuki
Format: Article
Language:English
Subjects:
Review (Invited)
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c304t-b537080de7f6ea4b7e18e0c03bb35bc5d2ef0d4e16d20b8fda120650ab31bc43
container_end_page 846
container_issue 8
container_start_page 837
container_title Japanese journal of clinical oncology
container_volume 54
creator Takakura, Toshiaki
Shimizu, Toshio
Yamamoto, Nobuyuki
description Abstract Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds to the specific antigen present at the cancer cells, allowing selective delivery of the cytotoxic agents to the tumor site. Several ADCs are approved by the US Food and Drug Administration for the treatment of hematologic cancers and solid tumors with clinically meaningful survival benefit. However, the development of ADCs faces a lot of challenges and there is a need to get better understanding of ADCs in order to improve patient outcomes. Here, we briefly discuss the structure and mechanism of ADCs, as well as the clinical data of current approved ADCs in solid tumors. This article reviews recent trends of ADCs’ drug development against solid tumors. The ability to deliver payloads selectively to targeting cancer cells potentially enable strengthen efficacy and improve safety profiles.
doi_str_mv 10.1093/jjco/hyae054
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11322887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jjco/hyae054</oup_id><sourcerecordid>3050940678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c304t-b537080de7f6ea4b7e18e0c03bb35bc5d2ef0d4e16d20b8fda120650ab31bc43</originalsourceid><addsrcrecordid>eNp9kE1Lw0AQhhdRrFZvnmVvejB2Nrv5EA9Sih-Fgpfel_2YtClptu4mSv69Ka1FL55m4H14Z3gIuWJwz-CBj1Yr40bLTiEk4oicMZEmEU9jdvxrH5DzEFYAkOQiOyUDnmcgYsHOyHRcN6V2tousbxfUuHrVLlSDgZY1Da4qLW3atfPhkdb4RUPj-3DR0cJ5alRt0NNmiV5tugtyUqgq4OV-Dsn85Xk-eYtm76_TyXgWGQ6iiXTCM8jBYlakqITOkOUIBrjWPNEmsTEWYAWy1Mag88IqFkOagNKcaSP4kDztajetXqM1WPcvVXLjy7XynXSqlH-TulzKhfuUjPE4zvOsb7jdN3j30WJo5LoMBqtK1ejaIDkk8CAgzfIevduhxrsQPBaHOwzk1r7c2pd7-z1-_fu3A_yjuwdudoBrN_9XfQPgipGM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3050940678</pqid></control><display><type>article</type><title>Antibody-drug conjugates in solid tumors; new strategy for cancer therapy</title><source>Oxford Journals Online</source><creator>Takakura, Toshiaki ; Shimizu, Toshio ; Yamamoto, Nobuyuki</creator><creatorcontrib>Takakura, Toshiaki ; Shimizu, Toshio ; Yamamoto, Nobuyuki</creatorcontrib><description>Abstract Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds to the specific antigen present at the cancer cells, allowing selective delivery of the cytotoxic agents to the tumor site. Several ADCs are approved by the US Food and Drug Administration for the treatment of hematologic cancers and solid tumors with clinically meaningful survival benefit. However, the development of ADCs faces a lot of challenges and there is a need to get better understanding of ADCs in order to improve patient outcomes. Here, we briefly discuss the structure and mechanism of ADCs, as well as the clinical data of current approved ADCs in solid tumors. This article reviews recent trends of ADCs’ drug development against solid tumors. The ability to deliver payloads selectively to targeting cancer cells potentially enable strengthen efficacy and improve safety profiles.</description><identifier>ISSN: 1465-3621</identifier><identifier>ISSN: 0368-2811</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyae054</identifier><identifier>PMID: 38704241</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Review (Invited)</subject><ispartof>Japanese journal of clinical oncology, 2024-05, Vol.54 (8), p.837-846</ispartof><rights>The Author(s) 2024. Published by Oxford University Press. 2024</rights><rights>The Author(s) 2024. Published by Oxford University Press.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c304t-b537080de7f6ea4b7e18e0c03bb35bc5d2ef0d4e16d20b8fda120650ab31bc43</cites><orcidid>0009-0001-4202-8058</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38704241$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takakura, Toshiaki</creatorcontrib><creatorcontrib>Shimizu, Toshio</creatorcontrib><creatorcontrib>Yamamoto, Nobuyuki</creatorcontrib><title>Antibody-drug conjugates in solid tumors; new strategy for cancer therapy</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Abstract Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds to the specific antigen present at the cancer cells, allowing selective delivery of the cytotoxic agents to the tumor site. Several ADCs are approved by the US Food and Drug Administration for the treatment of hematologic cancers and solid tumors with clinically meaningful survival benefit. However, the development of ADCs faces a lot of challenges and there is a need to get better understanding of ADCs in order to improve patient outcomes. Here, we briefly discuss the structure and mechanism of ADCs, as well as the clinical data of current approved ADCs in solid tumors. This article reviews recent trends of ADCs’ drug development against solid tumors. The ability to deliver payloads selectively to targeting cancer cells potentially enable strengthen efficacy and improve safety profiles.</description><subject>Review (Invited)</subject><issn>1465-3621</issn><issn>0368-2811</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNp9kE1Lw0AQhhdRrFZvnmVvejB2Nrv5EA9Sih-Fgpfel_2YtClptu4mSv69Ka1FL55m4H14Z3gIuWJwz-CBj1Yr40bLTiEk4oicMZEmEU9jdvxrH5DzEFYAkOQiOyUDnmcgYsHOyHRcN6V2tousbxfUuHrVLlSDgZY1Da4qLW3atfPhkdb4RUPj-3DR0cJ5alRt0NNmiV5tugtyUqgq4OV-Dsn85Xk-eYtm76_TyXgWGQ6iiXTCM8jBYlakqITOkOUIBrjWPNEmsTEWYAWy1Mag88IqFkOagNKcaSP4kDztajetXqM1WPcvVXLjy7XynXSqlH-TulzKhfuUjPE4zvOsb7jdN3j30WJo5LoMBqtK1ejaIDkk8CAgzfIevduhxrsQPBaHOwzk1r7c2pd7-z1-_fu3A_yjuwdudoBrN_9XfQPgipGM</recordid><startdate>20240504</startdate><enddate>20240504</enddate><creator>Takakura, Toshiaki</creator><creator>Shimizu, Toshio</creator><creator>Yamamoto, Nobuyuki</creator><general>Oxford University Press</general><scope>TOX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0001-4202-8058</orcidid></search><sort><creationdate>20240504</creationdate><title>Antibody-drug conjugates in solid tumors; new strategy for cancer therapy</title><author>Takakura, Toshiaki ; Shimizu, Toshio ; Yamamoto, Nobuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c304t-b537080de7f6ea4b7e18e0c03bb35bc5d2ef0d4e16d20b8fda120650ab31bc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Review (Invited)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takakura, Toshiaki</creatorcontrib><creatorcontrib>Shimizu, Toshio</creatorcontrib><creatorcontrib>Yamamoto, Nobuyuki</creatorcontrib><collection>Oxford Academic Journals (Open Access)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takakura, Toshiaki</au><au>Shimizu, Toshio</au><au>Yamamoto, Nobuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody-drug conjugates in solid tumors; new strategy for cancer therapy</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2024-05-04</date><risdate>2024</risdate><volume>54</volume><issue>8</issue><spage>837</spage><epage>846</epage><pages>837-846</pages><issn>1465-3621</issn><issn>0368-2811</issn><eissn>1465-3621</eissn><abstract>Abstract Antibody-drug conjugates (ADCs) have emerged as a novel class of anticancer treatment. ADCs are composed of three parts: a monoclonal antibody, a linker and a payload. A monoclonal antibody binds to the specific antigen present at the cancer cells, allowing selective delivery of the cytotoxic agents to the tumor site. Several ADCs are approved by the US Food and Drug Administration for the treatment of hematologic cancers and solid tumors with clinically meaningful survival benefit. However, the development of ADCs faces a lot of challenges and there is a need to get better understanding of ADCs in order to improve patient outcomes. Here, we briefly discuss the structure and mechanism of ADCs, as well as the clinical data of current approved ADCs in solid tumors. This article reviews recent trends of ADCs’ drug development against solid tumors. The ability to deliver payloads selectively to targeting cancer cells potentially enable strengthen efficacy and improve safety profiles.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>38704241</pmid><doi>10.1093/jjco/hyae054</doi><tpages>10</tpages><orcidid>https://orcid.org/0009-0001-4202-8058</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1465-3621
ispartof Japanese journal of clinical oncology, 2024-05, Vol.54 (8), p.837-846
issn 1465-3621
0368-2811
1465-3621
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11322887
source Oxford Journals Online
subjects Review (Invited)
title Antibody-drug conjugates in solid tumors; new strategy for cancer therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T09%3A18%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody-drug%20conjugates%20in%20solid%20tumors;%20new%20strategy%20for%20cancer%20therapy&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Takakura,%20Toshiaki&rft.date=2024-05-04&rft.volume=54&rft.issue=8&rft.spage=837&rft.epage=846&rft.pages=837-846&rft.issn=1465-3621&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyae054&rft_dat=%3Cproquest_pubme%3E3050940678%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c304t-b537080de7f6ea4b7e18e0c03bb35bc5d2ef0d4e16d20b8fda120650ab31bc43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3050940678&rft_id=info:pmid/38704241&rft_oup_id=10.1093/jjco/hyae054&rfr_iscdi=true